In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.

Includes supplementary material: sn.pub/extras

Klappentext
In the last decade advances in basic and clinical research on chronic leukemias and lymphomas-slowly progressive diseases of the blood and bone marrow-have produced a host of remarkable therapies, including the use of unique small molecules targeted at specific genetic lesions: pro-apoptotic drugs, monoclonal antibodies, and adoptive immunotherapy. In Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of chronic myeloproliferative and lymphoproliferative disorders, the authors place special emphasis on such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Among the disease models considered for chronic lymphocytic leukemia, low-grade lymphoma, and chronic myelogenous leukemia are impairments of the apoptotic mechanisms, as well as specific molecular events that initiate proliferation. Both models of oncogenesis may lead to novel therapeutic targets, such as purine nucleoside analogs for chronic lymphocytic leukemias, monoclonal antibodies for follicular lymphomas, and STI-571 (Gleevec) for chronic myelogenous leukemia.
Comprehensive and up-to-date, Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management is a unique book devoted to summarizing both the basic biology and the practical management of myeloproliferative disorders, low grade lymphomas, and chronic leukemias, distinguishing these disorders from large-cell lymphoma and Hodgkin's disease. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.

Zusammenfassung
Describing the unique biological features of indolent hematologic neoplasms, this work provides insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease.

Inhalt
1 Chronic Leukemias: History, Epidemiology, and Risk Factors.- 2 Chronic Lymphocytic Leukemia: Diagnosis and Management.- 3 Hairy Cell Leukemia: Biology, Diagnosis, and Treatment.- 4 Prolymphocytic Leukemias.- 5 Chronic Myeloid Leukemia.- 6 Sézary Syndrome: The Redefinition of a Clinico-Pathologic Entity and its Implication for Staging, Prognosis, and Treatment.- 7 Large Granular Lymphocyte Proliferative Diseases.- 8 Myeloproliferative Syndromes.- 9 Advances in the Biology and Treatment of Multiple Myeloma.- 10 Low-Grade Lymphoma.- 11 Aggressive Large-Cell Lymphomas.- 12 Hodgkin's Disease.